Cipla, India's third-largest drugmaker by sales, posted fourth-quarter profit above estimates on Tuesday and said it will ...

Cipla, India's No. 3 drugmaker by sales, reported a fourth-quarter profit that beat estimates on Tuesday, helped by strong ...

Vohra stated that the directive appears to be primarily aimed at branded pharmaceutical products rather than generic ...

Discover the Cipla Stock Liveblog, your go-to destination for real-time updates and comprehensive analysis of a ...

For the new financial year, Cipla expects its topline to see "continued growth trajectory" and the management fell short of ...

Managing Director & Global CEO Umang Vohra expressed confidence in the company's ability to expand, driven by a multi-pronged ...

The pharmaceutical segment contributed Rs 6,503.63 crore to the quarterly revenue, reflecting an 8.5 per cent growth, while ...

In addition, Jefferies expects Tata Motors to see a tough year ahead with the demand for Indian trucks growing soft and the ...

Along with the Q4 results, Cipla announced a final dividend of Rs 13 per equity share for the financial year 2025, and a ...

Nifty Pharma major Cipla is likely to deliver a strong set of numbers for the quarter ended March 2025, with broad-based ...

Pharma giant Cipla announced a significant 30 percent increase in consolidated net profit attributable to shareholders for ...

Cipla Ltd reported a robust 30% YoY increase in consolidated net profit, reaching Rs 1,222 crore for Q4 FY25, driven by ...